NASDAQ:MTCR

Metacrine Competitors

$4.45
-0.16 (-3.47 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.45
Now: $4.45
$4.66
50-Day Range
$4.61
MA: $7.22
$9.26
52-Week Range
$4.59
Now: $4.45
$16.19
Volume119,394 shs
Average Volume63,674 shs
Market Capitalization$116.63 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Metacrine (NASDAQ:MTCR) Vs. VRNA, SPPI, CPRX, VSTM, KALA, and ALT

Should you be buying MTCR stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Metacrine, including Verona Pharma (VRNA), Spectrum Pharmaceuticals (SPPI), Catalyst Pharmaceuticals (CPRX), Verastem (VSTM), Kala Pharmaceuticals (KALA), and Altimmune (ALT).

Metacrine (NASDAQ:MTCR) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Verona Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetacrineN/AN/AN/A
Verona PharmaN/A-115.93%-73.68%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Verona Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Metacrine00403.00
Verona Pharma00303.00

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Verona Pharma has a consensus price target of $19.00, indicating a potential upside of 137.50%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Verona Pharma.

Valuation and Earnings

This table compares Metacrine and Verona Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetacrineN/AN/AN/AN/AN/A
Verona PharmaN/AN/A$-40,780,000.00($3.10)-2.58

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 54.5% of Verona Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Verona Pharma on 4 of the 5 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Spectrum Pharmaceuticals (NASDAQ:SPPI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Spectrum Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetacrineN/AN/AN/A
Spectrum PharmaceuticalsN/A-98.90%-69.77%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Spectrum Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Metacrine00403.00
Spectrum Pharmaceuticals01302.75

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Spectrum Pharmaceuticals has a consensus price target of $9.75, indicating a potential upside of 225.00%. Given Metacrine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Spectrum Pharmaceuticals.

Valuation and Earnings

This table compares Metacrine and Spectrum Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetacrineN/AN/AN/AN/AN/A
Spectrum Pharmaceuticals$109.33 million4.22$-112,690,000.00($1.14)-2.63

Metacrine has higher earnings, but lower revenue than Spectrum Pharmaceuticals.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 63.6% of Spectrum Pharmaceuticals shares are held by institutional investors. 5.0% of Spectrum Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Spectrum Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Catalyst Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetacrineN/AN/AN/A
Catalyst Pharmaceuticals60.48%35.04%29.73%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Catalyst Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Metacrine00403.00
Catalyst Pharmaceuticals00403.00

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Catalyst Pharmaceuticals has a consensus price target of $7.6250, indicating a potential upside of 71.73%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Catalyst Pharmaceuticals.

Valuation and Earnings

This table compares Metacrine and Catalyst Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetacrineN/AN/AN/AN/AN/A
Catalyst Pharmaceuticals$102.31 million4.51$31.88 million$0.3014.80

Catalyst Pharmaceuticals has higher revenue and earnings than Metacrine.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 64.9% of Catalyst Pharmaceuticals shares are held by institutional investors. 11.7% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Catalyst Pharmaceuticals beats Metacrine on 6 of the 7 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Verastem's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetacrineN/AN/AN/A
Verastem-590.19%-189.37%-67.69%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Verastem, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Metacrine00403.00
Verastem00203.00

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Verastem has a consensus price target of $3.00, indicating a potential upside of 11.94%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Verastem.

Valuation and Earnings

This table compares Metacrine and Verastem's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetacrineN/AN/AN/AN/AN/A
Verastem$17.46 million26.35$-149,210,000.00($2.00)-1.34

Metacrine has higher earnings, but lower revenue than Verastem.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 42.2% of Verastem shares are held by institutional investors. 2.9% of Verastem shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Verastem on 6 of the 8 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Kala Pharmaceuticals (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Metacrine and Kala Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetacrineN/AN/AN/A
Kala Pharmaceuticals-1,794.36%-93.73%-43.09%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Kala Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Metacrine00403.00
Kala Pharmaceuticals01502.83

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Kala Pharmaceuticals has a consensus price target of $21.8333, indicating a potential upside of 192.28%. Given Metacrine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Kala Pharmaceuticals.

Valuation and Earnings

This table compares Metacrine and Kala Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetacrineN/AN/AN/AN/AN/A
Kala Pharmaceuticals$6.07 million75.75$-94,350,000.00($2.76)-2.71

Metacrine has higher earnings, but lower revenue than Kala Pharmaceuticals.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 67.6% of Kala Pharmaceuticals shares are held by institutional investors. 34.2% of Kala Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Metacrine beats Kala Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

Metacrine (NASDAQ:MTCR) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Insider & Institutional Ownership

52.3% of Metacrine shares are held by institutional investors. Comparatively, 66.2% of Altimmune shares are held by institutional investors. 2.7% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Metacrine and Altimmune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MetacrineN/AN/AN/A
Altimmune-659.33%-46.39%-38.32%

Valuation and Earnings

This table compares Metacrine and Altimmune's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MetacrineN/AN/AN/AN/AN/A
Altimmune$5.80 million78.59$-20,520,000.00($0.98)-12.52

Metacrine has higher earnings, but lower revenue than Altimmune.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Metacrine and Altimmune, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Metacrine00403.00
Altimmune00603.00

Metacrine currently has a consensus price target of $20.6667, indicating a potential upside of 364.42%. Altimmune has a consensus price target of $31.75, indicating a potential upside of 158.76%. Given Metacrine's higher possible upside, equities research analysts plainly believe Metacrine is more favorable than Altimmune.


Metacrine Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Verona Pharma logo
VRNA
Verona Pharma
1.7$8.00-3.3%$463.48 millionN/A-2.43
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$3.00-0.7%$461.18 million$109.33 million-2.21
Catalyst Pharmaceuticals logo
CPRX
Catalyst Pharmaceuticals
1.7$4.44-0.7%$460.98 million$102.31 million6.63Increase in Short Interest
Verastem logo
VSTM
Verastem
1.3$2.68-0.4%$460.07 million$17.46 million-1.90
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
1.7$7.47-1.9%$459.79 million$6.07 million-3.57
Altimmune logo
ALT
Altimmune
1.9$12.27-3.7%$455.83 million$5.80 million-6.17Increase in Short Interest
Molecular Templates logo
MTEM
Molecular Templates
2.0$8.12-7.3%$455.14 million$22.27 million-3.98Analyst Report
Insider Buying
Analyst Revision
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.8$2.96-3.4%$454.37 million$335 million-1.00
Viking Therapeutics logo
VKTX
Viking Therapeutics
1.6$5.87-3.7%$453.04 millionN/A-11.98News Coverage
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$5.36-4.5%$444.43 million$56.50 million0.00Analyst Downgrade
Inozyme Pharma logo
INZY
Inozyme Pharma
1.7$18.60-7.8%$436.43 millionN/A0.00Gap Down
BCEL
Atreca
1.7$11.81-3.6%$434.97 millionN/A-4.19
Selecta Biosciences logo
SELB
Selecta Biosciences
1.6$3.87-1.6%$434.88 million$6.68 million-4.66
MedAvail logo
MDVL
MedAvail
1.9$13.45-0.8%$429.59 million$1.03 million-3.30Increase in Short Interest
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$16.39-2.4%$426.29 millionN/A-3.44
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$11.50-2.4%$423.40 millionN/A0.00Lockup Expiration
ANI Pharmaceuticals logo
ANIP
ANI Pharmaceuticals
1.9$34.18-1.7%$422.64 million$206.55 million-17.18
XOMA logo
XOMA
XOMA
1.3$37.50-0.9%$422.18 million$18.37 million-33.78Increase in Short Interest
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.3$5.26-0.4%$411.77 million$380,000.000.00Analyst Upgrade
News Coverage
Puma Biotechnology logo
PBYI
Puma Biotechnology
1.4$10.07-1.4%$405.40 million$272.30 million-7.04
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
0.9$20.23-0.4%$400.47 million$362.21 million24.37
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$8.17-2.7%$392.29 million$3.89 million-4.28Gap Down
Cue Biopharma logo
CUE
Cue Biopharma
1.3$12.84-0.9%$391.07 million$3.46 million-8.18News Coverage
Fortress Biotech logo
FBIO
Fortress Biotech
1.4$4.12-7.8%$391.02 million$36.63 million-4.85Gap Up
Sesen Bio logo
SESN
Sesen Bio
1.2$2.30-0.9%$389.59 millionN/A-5.23Decrease in Short Interest
DURECT logo
DRRX
DURECT
1.4$1.71-4.7%$388.52 million$29.56 million-34.19
BeyondSpring logo
BYSI
BeyondSpring
1.2$9.80-2.7%$383.59 millionN/A-4.80
UroGen Pharma logo
URGN
UroGen Pharma
1.8$18.35-1.0%$383.46 million$20,000.00-2.87Gap Down
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.22-4.7%$383.40 million$1.98 million-3.75
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$12.93-3.2%$381.49 million$18.15 million-3.04Increase in Short Interest
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.38-3.8%$380.35 million$28.91 million-5.63Analyst Upgrade
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$11.53-3.4%$376.71 millionN/A-4.00
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.01-1.4%$375.61 million$16.54 million-3.26
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.50-4.7%$375.37 million$9.48 million-0.25News Coverage
Athenex logo
ATNX
Athenex
1.6$3.97-3.8%$371.02 million$101.23 million-2.72Increase in Short Interest
Gap Up
Athersys logo
ATHX
Athersys
1.3$1.69-1.8%$363.76 million$5.63 million-4.57
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$15.60-4.2%$363.51 millionN/A0.00
BELLUS Health logo
BLU
BELLUS Health
1.7$4.58-4.1%$358.78 million$30,000.00-7.76
Oncorus logo
ONCR
Oncorus
1.7$13.68-3.5%$350.55 millionN/A0.00Increase in Short Interest
News Coverage
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.0$9.93-0.3%$347.07 millionN/A0.00
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.42-1.5%$344.95 million$111.39 million24.43
Homology Medicines logo
FIXX
Homology Medicines
1.6$6.81-3.2%$343.82 million$1.67 million-2.49
Theratechnologies logo
THTX
Theratechnologies
1.1$3.60-0.0%$337.83 million$63.22 million-11.61Earnings Announcement
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$7.10-3.9%$329.40 million$6.29 million-4.08
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$9.59-2.2%$327.77 million$28.95 million-13.70Increase in Short Interest
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$12.54-0.9%$325.66 million$11.94 million-7.65Analyst Report
Analyst Revision
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.6$12.69-7.9%$322.85 millionN/A-9.61Analyst Report
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$6.48-5.4%$319.88 million$2.42 million-5.68Analyst Report
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$0.98-6.1%$317.44 millionN/A-0.28Increase in Short Interest
Gap Up
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$6.27-1.1%$307.21 million$15.98 million-1.11Decrease in Short Interest
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.